Bristol Myers Squibb Reports Five-Year CheckMate-227 Data for Opdivo Plus Yervoy in NSCLC

Bristol Myers Squibb today presented five-year overall survival data from the Phase 3 CheckMate-227 trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) versus chemotherapy in patients with previously untreated metastatic non-small cell lung cancer. The data showed that 24% of patients in the Opdivo plus Yervoy arm were alive at five years compared to 14% in the chemotherapy arm.